KIR2DL3 Receptor: A Potential Drug Target for Cancer and Chronic Pain

Target Name: KIR2DL3

NCBI ID: G3804

KIR2DL3

KIR2DL3 Receptor: A Potential Drug Target for Cancer and Chronic Pain

The KIR2DL3 gene is located on chromosome 6p21.3 and encodes for the killer T-cell receptor (KCR), also known as the KIR2DL3 receptor. The KCR is a type of surface receptor that is expressed in the T-cells, which are a type of immune cell that play a crucial role in the immune system.

The KIR2DL3 receptor is involved in the immune response by allowing T-cells to recognize and respond to foreign antigens. The KIR2DL3 receptor is a member of the immunoglobulin superfamily and is composed of a constant region, a variable region, and a cytoplasmic tail. The constant region of the KIR2DL3 receptor includes the extracellular domain, which is involved in cell signaling, while the variable region includes the variable regions that are involved in recognition of antigens. The cytoplasmic tail of the KIR2DL3 receptor is involved in cell adhesion and signaling.

The KIR2DL3 receptor is involved in many different immune responses, including the immune response against viruses, tumors, and intracellular infections. KIR2DL3 receptor antagonists have been shown to be effective in treating various types of cancer, including breast, ovarian, and skin cancers. They have also been shown to be effective in treating autoimmune diseases, such as rheumatoid arthritis and lupus.

In addition to its potential as a drug target, the KIR2DL3 receptor is also being investigated as a potential biomarker for certain types of cancer. The KIR2DL3 receptor is often expressed in higher levels in cancer cells compared to healthy cells, making it a potential biomarker for cancer. Additionally, the KIR2DL3 receptor is also expressed in normal tissues, such as skin and hair, making it a potential biomarker for certain types of cancer.

The KIR2DL3 receptor is also being studied as a potential therapeutic target for treating chronic pain. Chronic pain is a common condition that affects millions of people worldwide and can have a significant impact on quality of life. The KIR2DL3 receptor has been shown to be involved in the immune response and has been suggested as a potential therapeutic target for treating chronic pain.

In conclusion, the KIR2DL3 receptor is a unique and important molecule that plays a crucial role in the immune system. Its potential as a drug target and biomarker make it an attractive target for researchers to study and develop new treatments for a variety of diseases. Further research is needed to fully understand the role of the KIR2DL3 receptor in the immune system and its potential as a therapeutic target.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3

Functions: Receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). Inhibits the activity of NK cells thus preventing cell lysis

The "KIR2DL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR2DL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets